GlassScriptPhysician profile
Sarah Slone
NPI 1225501653
$639.83
in general payments reported to CMS, 2019-2025
14 companies · $79.82 in 2025
The $79.82 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.58 · 2023: $310 · 2024: $207 · 2025: $79.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143.66 | 2022-2024 | |
| Exact Sciences Corporation | $112.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alkermes, INC. | $63.74 | 2023 | Aristada, Vivitrol, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $62.62 | 2022-2023 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $59.32 | 2023 | Spravato, Invega Sustenna |
| Lilly USA, LLC | $42.37 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $39.82 | 2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $25.11 | 2023 | Auvelity |
| Currax Pharmaceuticals LLC | $16.60 | 2023 | Contrave, Onzetra Xsail |
| Amgen INC. | $16.37 | 2024 | Otezla, Repatha |
| Shield Therapeutics INC | $15.72 | 2024 | |
| Indivior INC. | $14.53 | 2023 | Sublocade |
| Paratek Pharmaceuticals, INC. | $14.34 | 2024 | Nuzyra |
| Pfizer INC. | $13.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Slone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.